Heterocyclic Compounds

Matches 201 - 250 out of 15,438	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2023/221022A1	METHOD FOR PREPARING GALANTHAMINE, DERIVATIVE THEREOF AND INTERMEDIATE THEREOF Disclosed in the present invention are intermediate I and intermediate II which have structural formulas as represented by formula (I) and formula (II), respectively, and can be used for preparing galantamine, and a preparation method th...
WO/2023/217230A1	KINESIN KIF18A INHIBITOR AND USE THEREOF The present invention provides a KIF18A inhibitor and a method for synthesizing same. The compound of the present invention can regulate KIF18A protein to influence the cell cycle and the cell proliferation process, so as to treat cancer...
WO/2023/216956A1	CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a camptothecin compound with anti-tumor activity, a preparation method therefor and use thereof. In particular, the present invention relates to a compound of the following formula or a pharmaceutically a...
WO/2023/220439A1	COMPOSITIONS USEFUL FOR MODULATING SPLICING Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/220433A1	COMPOSITIONS USEFUL FOR MODULATING SPLICING Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/218245A1	HETEROARYL DERIVATIVE COMPOUNDS, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF The present invention relates to heteroaryl derivative compounds and a pharmaceutical composition comprising thereof. Specifically, the present invention relates to heteroaryl derivative compounds having RAF inhibitory activity.
WO/2023/217227A1	CAMPTOTHECIN DERIVATIVE AND LIGAND-DRUG CONJUGATE The present disclosure relates to a ligand-drug conjugate of a novel structure or a pharmaceutically acceptable salt thereof. Specifically, the present disclosure provides a ligand-drug conjugate having a structural general formula repre...
WO/2023/217064A1	CAMPTOTHECIN DERIVATIVE, ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL COMPOSITION BASED ON SAME, AND USE THEREOF The present invention belongs to the field of pharmaceutical chemistry, and relates to a camptothecin derivative, an antibody-drug conjugate and pharmaceutical composition based on same, and the use thereof. The derivative has a structur...
WO/2023/217906A1	PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE The present disclosure relates to compounds of Formula (I) that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are useful for preventin...
WO/2023/220541A1	TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Tetrahydropyrido[3,4-d]pyrimidine compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly hum...
WO/2023/220435A1	COMPOSITIONS USEFUL FOR MODULATING SPLICING Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
WO/2023/214651A1	HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME The present invention relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting element comprising same.
WO/2023/214650A1	HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME The present invention relates to a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
WO/2023/215238A1	PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES Described herein are new 8,9-dialoxy-7-azaindenoisoquinoline compounds (I), processes for their preparation, and methods of their use in the treatment of diseases responsive to inhibition of topoisomerase 1 and/or binding to the c-MYC G-...
WO/2023/214836A1	NOVEL BERBERINE ANALOGUE AND USE THEREOF The present invention relates to a novel berberine analogue CD1-410. It has been identified that the novel berberine analogue promotes the activity of mitophagy, and thus can reduce mitochondria with a damaged structure and/or function. ...
WO/2023/207991A1	FUSED QUINAZOLINE COMPOUND AND USE THEREOF Disclosed in the present invention are a fused quinazoline compound and the use thereof. Specifically, the present invention relates to a compound as represented by formula (IV) and a pharmaceutically acceptable salt thereof.
WO/2023/212219A1	TRICYCLIC PARP1 INHIBITORS AND USES THEREOF Described herein are tricyclic PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.
WO/2023/206274A1	ORGANIC ELECTROLUMINESCENT DIODE AND DISPLAY PANEL The present disclosure provides an organic electroluminescent diode and a display panel, belonging to the technical field of display. The organic electroluminescent diode comprises an anode, a luminescent layer, a hole blocking layer, an...
WO/2023/207773A1	LIGAND-DRUG CONJUGATE OF CAMPTOTHECIN ANALOGS, INTERMEDIATES, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Provided are conjugates of novel camptothecin analogs with a cell binding molecule of formula (I). It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of application the c...
WO/2023/212240A1	COMPOUNDS FOR INHIBITING KIF18A The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods o...
WO/2023/210623A1	HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
WO/2023/210192A1	COMPOUND, LIGHT-EMITTING MATERIAL, AND ORGANIC LIGHT-EMITTING DEVICE This compound, represented by a general formula, is useful in a light-emitting device. Ar1 is a benzene ring, a naphthalene ring, a phenanthrene ring, or the like; D is a 5H-benzofuro[3,2-c]carbazol-5-yl group, or the like; A is a cyano ...
WO/2023/211990A1	BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-ga...
WO/2023/201421A1	INDOLINE DERIVATIVES AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO The present application relates to indoline derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating...
WO/2023/201429A1	HOMOHARRINGTONINE AND PACLITAXEL COMBINATION FOR THE TREATMENT OF BREAST CANCER The present application relates to combination treatments for breast cancer. For example, the application relates to the use of homoharringtonine and paclitaxel for the treatment of breast cancer including, for example, triple negative b...
WO/2023/204631A1	CAMPTOTHECIN DERIVATIVES THAT BIND TO DDX5 PROTEIN AND PRODRUGS THEREOF The present invention relates to: (a) an active camptothecin derivative represented by chemical formula 1, which is designed to bind to a DDX5 protein or E3 ligase; (b) a prodrug thereof designed to release the active camptothecin deriva...
WO/2023/201780A1	METHOD FOR PREPARING QUINOLONE COMPOUND AND INTERMEDIATE THEREOF Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...
WO/2023/205251A1	COMPOUNDS ACTIVE TOWARDS BROMODOMAINS Disclosed are compounds of formula (I) which modulate bromodomains, pharmaceutical compositions containing said compounds and use of said compounds in therapy.
WO/2023/205468A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/198114A1	ALK2 KINASE INHIBITOR An ALK2 kinase inhibitor as represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor, and use of the ALK2 kinase inhibitor in preparing a drug for the prevention and/or treatment of indicati...
WO/2023/200441A1	ANTIVIRAL HETEROCYCLIC COMPOUNDS The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumo virus (HMPV) inhibitors. ...
WO/2023/198078A1	POLYCYCLIC COMPOUNDS AS KRAS G12D INHIBITORS The present invention provides compounds as KRAS G12D inhibitors. Specifically, the present invention provides compounds having a structure represented by formula (I), or optical isomers, pharmaceutically acceptable salts, prodrugs, deut...
WO/2023/201012A1	IKZF2 DEGRADERS AND USES THEREOF Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
WO/2023/200964A1	PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...
WO/2023/196538A1	GPR35 MODULATORS AND USES THEREOF Substituted benzofuran, benzothiophene, and indole carboxamide compounds, conjugates, and pharmaceutical compositions for use as immunotherapeutics in the treatment of cancer, such as solid tumors, are disclosed herein. The disclosed com...
WO/2023/195530A1	URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME The present invention provides a compound showing coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. A compound represented by formula (I) [in...
WO/2023/196875A1	BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF The present disclosure relates generally to compounds, of Formula I: Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or...
WO/2023/195529A1	URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...
WO/2023/194964A1	FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein α, β, m, R5, R6, R7, R9, R10, R11, Ra, Rb, X1, X2, X3, X4 and X8 are defined in the specification. This disclosure also relates to materials...
WO/2023/191536A1	THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF The present invention relates to a thiobenzimidazole derivative or a pharmaceutically acceptable salt thereof, and a composition for preventing or treating cancer, the composition comprising the derivative as an active ingredient. The th...
WO/2023/191533A1	THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR The present invention relates to a thiobenzimidazole derivative preparation method, a novel intermediate therefor, and the like. The present invention uses an intermediate containing O-ethyl carbonodithioate or an intermediate containing...
WO/2023/192328A1	AN OXAZIRIDINE PLATFORM FOR TARGETING FUNCTIONAL ALLOSTERIC METHIONINE SITES The present disclosure features compounds (e.g., oxaziridine-based compounds), as well as related compositions and methods of use thereof, e.g., for selectively labeling a methionine residue in a target peptide or protein.
WO/2023/187099A1	SYNTHESIS OF MORPHINANS WITH REDUCED HERG ACTIVITY AND MOP BINDING The invention relates to morphinan-derivatives, processes for their preparation, medicaments containing them and the use of these morphinan-derivatives for the preparation of medicaments.
WO/2023/192112A1	PROCESS FOR PREPARING SHP2 INHIBITORS Provided herein are methods for preparing a SHP2 inhibitor and intermediates useful therein.
WO/2023/192801A1	SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS The present disclosure provides certain sulfonamido derivatives that are Cyciin-dependent kinase 2 (CDK2) inhibitors of Formula (I): for the treatment of diseases treatable by inhibition of CDK2. Also provided are pharmaceutical composit...
WO/2023/192653A1	PROBES FOR FLUORESCENCE IMAGING The present disclosure provides photocleavable rhodamine probes that facilitate live- and fixed-cell immunofluorescence. The ultra-fast spirocyclization of the dye following cleavage depletes the fluorescence signal, enabling cyclic mult...
WO/2023/183520A1	COMPOSITIONS AND METHODS FOR TREATING CANCER Disclosed herein are inhibitors of TACC and methods of treating certain diseases and disorders (e.g., diseases and disorders related to TACC).
WO/2023/183607A1	CEREBLON LIGANDS AND USES THEREOF Described herein are compounds or conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading c...
WO/2023/181952A1	COMPOUND, POLYMER COMPOUND, COMPOSITION, AND LIGHT EMITTING DEVICE This compound is represented by formula (1). [In the formula, Ar1 represents an aromatic hydrocarbon ring or an aromatic heterocycle. Ring Ar2 and ring Ar3 each independently represent an aromatic hydrocarbon ring or an aromatic heterocy...
WO/2023/179275A1	FUSED RING UNIT BASED ON QUINOXALINE DERIVATIVE, SMALL MOLECULE CONTAINING SAME, POLYMER, PREPARATION METHODS AND USE Disclosed in the present invention are a fused ring unit based on a quinoxaline derivative, a small molecule containing same, a polymer, and preparation methods therefor and the use thereof. In the present invention, a new aromatic unit ...

Matches 201 - 250 out of 15,438	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >